Detalhe da pesquisa
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043558
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621400
3.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet
; 401(10379): 821-832, 2023 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774933
4.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
5.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33616314
6.
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
BJU Int
; 133 Suppl 3: 57-67, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37986556
7.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858721
8.
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
Eur J Nucl Med Mol Imaging
; 51(1): 295-303, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592084
9.
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Lancet Oncol
; 23(6): 768-780, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489363
10.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581798
11.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273926
12.
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Gynecol Oncol
; 163(1): 72-78, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34412908
13.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103386
14.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359490
15.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(5): 699-709, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305099
16.
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol
; 159(1): 101-111, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861537
17.
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
Int J Gynecol Cancer
; 30(8): 1239-1242, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32591370
18.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10106): 1949-1961, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28916367
19.
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort.
Eur Urol Focus
; 2024 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195354
20.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
J Clin Oncol
; 42(11): 1222-1228, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38227898